ACP supports QPP measure 310: "Chlamydia Screening in Women" because it aligns with United States Preventive Services Task Force (USPSTF) and the Centers for Disease Control and Prevention (CDC) recommendations on chlamydia screening, evidence supports screening in primary care as feasible and effective, and the denominator is clearly specified to capture all women who are sexually active. Specifications define three methods to identify contraceptive therapy prescription: 1) pharmacy data, 2) claims data, 3) medical records data.